Amgen's Tezepelumab Reduces Exacerbations In Patients With Severe Asthma & Comorbid Nasal Polyps

(RTTNews) - Amgen (AMGN) said new data from the pivotal NAVIGATOR Phase 3 trial demonstrated that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.

Tezepelumab is a potential first-in-class treatment that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine, and has the potential to treat a broad population of patients with severe asthma.

Tezepelumab is being developed by Amgen in collaboration with AstraZeneca.

The pre-specified exploratory analysis evaluated the effect of tezepelumab in NAVIGATOR patients with or without reported nasal polyps (NP+ or NP-) in the past two years. The analysis showed tezepelumab achieved an 86% reduction in the annualized asthma exacerbation rate in NP+ patients and 52% in NP- patients over 52 weeks, compared to placebo when added to standard of care.